Safeplus International Holdings Ltd. (ACAI)

[RedShoulder]

SmallCap digest touts BIPH, received this in an e-mail:

Biophan/Boston Scientific Announce (some) Deal Terms.

I have to admit to a small personal bias. I like Biophan (OTCBB: BIPH). We first brought it to the readership on December 19th 2003 at 35 cents. Currently $2.68, that increase represents almost an eight-fold return. As well many profitable trading opportunities have appeared since our initial Alert. We strongly believe that there is more to come.

Not only am I impressed with Biophan's technology and business plans, but also with the company's focus and impressive execution in what is by all measure a reasonably short period of time.

Today's announcement (release below) of some of the deal terms with Boston Scientific (NYSE: BSX) is important for more than the money and prestige of securing a top-tier partner. It's likely the catalyst that will allow the company to leave the confines of the OTCBB and gain a listing on a senior exchange. The larger an exchange, the more investors, money and muscle will be directed toward a company.

Biophan has done an amazing job from being just a vision a couple of years ago to reaching a point that could well take into the big leagues--hopefully soon. As the press release states:

The license agreement and an accompanying investment agreement provide for $5.75 million to be paid to Biophan by August 15, 2005, which the Company indicates will be sufficient to allow it to file for a listing on a major stock exchange.

Here is the balance of the known details as released in the 10Q:

License agreement covers multiple patents related to Magnetic Resonance Imaging (MRI) safety and image compatibility.
Exclusive area of the arrangement includes vascular implants
Non-exclusive areas cover a broad array of products
Royalty rates ranging from 3% to 5%.
Boston Scientific has the right to sub-license the exclusive product areas to third parties, with Biophan and Boston Scientific to share all proceeds from these parties.
Provision for milestone payments (potentially millions per product) to Biophan for specific product areas
Initial upfront payment to Biophan of $750,000
Boston Scientific to invest $5 million in Biophan.
A resultant increase in interest and activity with other manufacturers.
For more information, the company's 10-Q filed Friday can be found here:
http://ir.10kwizard.com/contents.php?ipage=3575180&repo=tenk&source=104
It's all good information, but especially check out page15 re BSX.
Take Heart…

In our opinion, the cool part of this announcement is the vascular implant portion of the deal. Vascular implants include stents and vena cava filters. While BIPH has been known for its MRI safety technology for devices such as pacemakers, this inclusion of its technology for improving the safety and efficacy of devices such as stents is very material. It not only further validates the company's technology, but also adds strength to the wide-ranging influence and licensing potential of Biophan's significant--and growing-- intellectual property portfolio. We expect that there will be more deals of this quality to come.

As the company has oft-stated, including within today's filing:

"It is our goal to one day see all biomedical devices be MRI safe and image compatible, and we feel that the Boston Scientific agreement facilitates this goal."

So far so good, it seems…

We'll resist putting in retracement lines as BIPH's share price has always been pretty much news driven. Monday will likely see significant activity and volume, so we felt that profit objectives would be more useful. Although the shares can be volatile, based on our technical perspective, it appears that conservative investors might take a hard look should the shares hit $3.06, while the more aggressive among us might see $3.49 as an appropriate profit target. We have noted these levels with blue lines on the chart.

That said, we continue to suggest strategic accumulation of Biophan for long-term investors.

Biophan Outlines Recent Activities in SEC Form 10-Q for Quarter Ended May 31, 2005
Quarterly Report Provides Additional Details of Licensing Agreement with Boston Scientific

ROCHESTER, N.Y.--(BUSINESS WIRE)--July 15, 2005--Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, has released additional details of its recently executed technology licensing agreement with medical device manufacturer Boston Scientific (NYSE: BSX) in its SEC Form 10-Q.

As described in the quarterly report, Biophan's definitive license agreement with Boston Scientific covers multiple patents related to Magnetic Resonance Imaging (MRI) safety and image compatibility. The agreement includes both exclusive and non-exclusive product categories. The license agreement and an accompanying investment agreement provide for $5.75 million to be paid to Biophan by August 15, 2005, which the Company indicates will be sufficient to allow it to file for a listing on a major stock exchange

"The transaction with Boston Scientific has provided a validation point for our technology that has resulted in increased interest and activity with other manufacturers," the Company said in the quarterly report. "It is our goal to one day see all biomedical devices be MRI safe and image compatible, and we feel that the Boston Scientific agreement facilitates this goal."

Information about the agreements between Biophan and Boston Scientific can be found in the quarterly report in the section entitled "Item 2, Plan of Operation," under the subheading, "Boston Scientific License." Biophan's SEC Form 10-KSB can be viewed by visiting www.sec.gov.

In addition, the quarterly report also provides an extensive overview of Biophan's overall business strategy, proprietary technologies and products, and recent key achievements in its effort to deliver advanced solutions to multi-billion-dollar biomedical market segments.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents. Biophan is developing other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 142 U.S. patents, licenses, or applications. This total includes 38 issued U.S. patents, 9 recently-allowed applications that will issue as patents in the near future, and 95 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific (NYSE: BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

FYI... %^ greeneyedhawk